Ph.D. Molecular Pharmacology · Science Contributor
Ph.D. Molecular Pharmacology · Drug-Receptor Interaction Research · Science Contributor, PurePep Vital
Dr. Webb is a molecular pharmacologist specialising in drug-receptor interaction studies and peptide-based therapeutic leads in preclinical models. His research examines GLP-1 receptor binding kinetics and downstream cAMP signalling in islet cell research. He contributes compound mechanism content and COA interpretation guides to PurePep Vital, with a focus on metabolic peptides and incretin biology.
Review scope
GLP-1 pharmacology · Incretin biology · Certificate of Analysis interpretation
Editorial role
Ph.D. Molecular Pharmacology · Science Contributor
Standards
COA and RUO review policyBPC-157, TB-500, and CJC-1295 are among the compounds facing new regulatory scrutiny in 2026. This research-use-only primer explains what changed, what remains available as RUO materials, and what documentation researchers should maintain.
Tendon repair research models involve distinct peptides targeting angiogenesis, actin dynamics, and matrix remodeling—compared here with RUO sourcing navigation.
Social channels amplify incretin peptide discussions; this article contrasts Reddit narratives with trial-published endpoints for research literacy.
Semaglutide, tirzepatide, and retatrutide represent single, dual, and triple incretin receptor agonism. This guide compares their mechanisms and published research context so laboratories can choose the right compound for a study.